Diabetes

Metabolic Diseases
539
Pipeline Programs
30
Companies
50
Clinical Trials
25
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
208
1
30
2
184
114
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
15698%
Small Molecule
43%
+ 554 programs with unclassified modality

On Market (25)

Approved therapies currently available

U
AFREZZAApproved
insulin human
Unknown Company
Insulin [EPC]inhalation2014
U
EMPAGLIFLOZINApproved
empagliflozin
Unknown Company
oral
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
Novo Nordisk
LEVEMIRApproved
insulin detemir
Novo Nordisk
injection2005
Novo Nordisk
LEVEMIR FLEXPENApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR FLEXTOUCHApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR INNOLETApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR PENFILLApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
U
MEZOFYApproved
aripiprazole
Unknown Company
oral2025
Novo Nordisk
NOVOLIN 70/30Approved
human insulin
Novo Nordisk
Insulin [EPC]injection1991
Novo Nordisk
NOVOLIN NApproved
human insulin
Novo Nordisk
Insulin [EPC]injection1991
Novo Nordisk
NOVOLIN RApproved
human insulin
Novo Nordisk
Insulin [EPC]injection1991
Novo Nordisk
NOVOLOG MIX 70/30Approved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
Novo Nordisk
NOVOLOG MIX 70/30 FLEXPENApproved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
Novo Nordisk
NOVOLOG MIX 70/30 PENFILLApproved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
U
OPIPZAApproved
aripiprazole
Unknown Company
Atypical Antipsychotic [EPC]oral2024
Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
U
PIOGLITAZONE HYDROCHLORIDEApproved
pioglitazone
Unknown Company
Peroxisome Proliferator Receptor alpha Agonist [EPC]oral2018
U
PRANDINApproved
repaglinide
Unknown Company
oral1997
U
REPAGLINIDEApproved
repaglinide
Unknown Company
Glinide [EPC]oral2014
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novo Nordisk
TRESIBAApproved
insulin degludec
Novo Nordisk
Insulin Analog [EPC]subcutaneous2015
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2021

Competitive Landscape

34 companies ranked by most advanced pipeline stage

Novo Nordisk
642 programs
202
25
181
82
Aspart fixed dosePhase 41 trial
Insulin AspartPhase 41 trial
Insulin detemirPhase 41 trial
Insulin detemirPhase 41 trial
NovoFine® needle 6 mmPhase 41 trial
+637 more programs
Active Trials
NCT03374774Completed516Est. Jul 2018
NCT03022344Unknown200Est. Oct 2021
NCT01186003Completed30Est. May 2014
+638 more trials
Sanofi
6 programs
1
2
Glargine insulinPhase 41 trial
LantusPhase 42 trials
GlarginePhase 12 trials
Diabetes Digital InterventionN/A1 trial
Insulin glargineN/A1 trial
+1 more programs
Active Trials
NCT03870997Completed94,321Est. Apr 2019
NCT03703869Completed4,589Est. Feb 2020
NCT01197742Completed2,772Est. Oct 2009
+5 more trials
Providence Therapeutics
4 programs
1
1
Switching to NPH insulinPhase 41 trial
MEDICPhase 31 trial
Behavioral activationN/A1 trial
Strict Glycemic Control for one year post-op CABGN/A
Active Trials
NCT02027259CompletedEst. Oct 2015
NCT00409240CompletedEst. Jun 2008
NCT01854723WithdrawnEst. Dec 2015
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
EmpagliflozinPhase 4Small Molecule1 trial
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional DatabaseN/A1 trial
Long- and intermediate- acting insulinsN/A1 trial
Active Trials
NCT04903496Completed1,233,162Est. Jun 2022
NCT02922179Completed103,951Est. Jan 2019
NCT02998970Unknown97Est. Sep 2018
ConvaTec
ConvaTecNJ - Bridgewater
2 programs
1
Convatec engenex negative pressure wound therapyPhase 41 trial
Aquacel® Ag+ ExtraN/A1 trial
Active Trials
NCT02228122CompletedEst. May 2015
NCT01108276WithdrawnEst. Nov 2011
Novartis
NovartisBASEL, Switzerland
2 programs
1
aliskiren 300 mg once dailyPhase 41 trial
Real-world Aliskiren Use in Diabetic PatientsN/A1 trial
Active Trials
NCT01393860Completed200
NCT01349114Terminated21Est. Jan 2012
Lantheus Medical Imaging
1 program
1
Technetium Tc99m SestamibiPhase 41 trial
Active Trials
NCT00162344CompletedEst. Dec 2005
Bristol Myers Squibb
3 programs
1
1
DapagliflozinPhase 3Small Molecule
Insulin, glucose and staple isotopesPhase 11 trial
Application ValidationN/A1 trial
Active Trials
NCT05303051Withdrawn0Est. Apr 2025
NCT01152372Completed36Est. Nov 2010
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
3 programs
1
Insulin Efsitora AlfaPhase 31 trial
DRMSN/A1 trial
No treatment givenN/A1 trial
Active Trials
NCT01354015Completed98Est. Sep 2014
NCT01511393Enrolling By Invitation6,750Est. Dec 2039
NCT05362058Completed928Est. Apr 2024
Pfizer
PfizerNEW YORK, NY
3 programs
1
AripiprazolePhase 2/3Small Molecule3 trials
Long- and intermediate- acting insulinsN/A
lipitorN/A1 trial
Active Trials
NCT00770679Terminated16Est. Jul 2012
NCT00910780Withdrawn0Est. Nov 2009
NCT00347425Completed286Est. Feb 2008
+1 more trials
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
Self-management of chronic illnessPhase 2/31 trial
Active Trials
NCT00238836UnknownEst. Mar 2006
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
1
RO 205-2349Phase 21 trial
;Accu-Chek Compact Plus LCM bulk JapanN/A1 trial
Accu-Chek 360 softwareN/A1 trial
Active Trials
NCT01820169Terminated2Est. Dec 2013
NCT00956800Completed100Est. Jun 2011
NCT00057304Completed190Est. Mar 2004
Pulse Biosciences
Pulse BiosciencesCA - Hayward
3 programs
1
Whole wheat banana breadPhase 21 trial
ControlN/A1 trial
Dietary pulsesN/A1 trial
Active Trials
NCT02402517CompletedEst. Dec 2017
NCT01605422UnknownEst. Dec 2015
NCT00877968Completed
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
MBX-2982Phase 2
MBX-2982Phase 21 trial
Active Trials
NCT01035879Completed100Est. Aug 2010
R
ResVerlogiXAB - Calgary
1 program
1
RVX000222Phase 21 trial
Active Trials
NCT01728467Completed20Est. Mar 2014
CT
1 program
1
Polysaccharide superparamagnetic iron oxide injectionPhase 1/21 trial
Active Trials
NCT06051565CompletedEst. Sep 2022
M&
Merck & Co.RAHWAY, NJ
6 programs
3
Isoglycemic ClampPhase 12 trials
Stable isotope tracerPhase 11 trial
TedizolidPhase 11 trial
Advanced CareN/A1 trial
GLP-1N/A1 trial
+1 more programs
Active Trials
NCT01979471Completed723Est. Dec 2015
NCT00588380Completed88Est. Sep 2010
NCT01152242Completed36Est. May 2012
+3 more trials
Paratek Pharmaceuticals
1 program
1
OmadacyclinePhase 1Small Molecule1 trial
Active Trials
NCT04144374CompletedEst. Jul 2021
Bayer
4 programs
4 blood glucose monitoring systemsN/A1 trial
6 blood glucose monitoring systems for self-testingN/A1 trial
Blood glucose monitoring systems for self-testingN/A1 trial
Blood glucose monitoring systems for self-testingN/A1 trial
Active Trials
NCT01789021Completed120Est. Apr 2013
NCT02531386Completed120Est. Nov 2015
NCT02461394Completed150
+1 more trials
Abbott
AbbottABBOTT PARK, IL
4 programs
CGM System for Type 1 and Type 2 Diabetes MellitusN/A1 trial
Continuous Glucose MonitoringN/A1 trial
FreeStyle Navigator II Continuous Glucose Monitoring SystemN/A1 trial
Standard ONSN/A1 trial
Active Trials
NCT00465881Completed30Est. Apr 2006
NCT07135531Not Yet Recruiting50Est. Jul 2027
NCT01455064Completed31Est. Jan 2012
+1 more trials
AstraZeneca
3 programs
Diabetic Under 70 (Diabetics Below 70)N/A1 trial
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.N/A1 trial
The Effect of Injectable Therapies on Quality of Life in DiabetesN/A1 trial
Active Trials
NCT00516204Completed685Est. Dec 2007
NCT00681850Completed4,027Est. Jan 2010
NCT03222245Completed256Est. Sep 2022
Biolinq
BiolinqCA - San Diego
2 programs
Biolinq SystemN/A1 trial
The Biolinq MicroArray Intradermal Continuous Glucose Biowearable SystemN/A1 trial
Active Trials
NCT06229743Completed247Est. Jun 2024
NCT06560177Completed31Est. Sep 2024
Alliance Pharmaceuticals
2 programs
Home VisitiationN/A1 trial
TOD Great PlainsN/A1 trial
Active Trials
NCT03374098Unknown150Est. Dec 2022
NCT06770673Recruiting140Est. Oct 2028
Insulet
InsuletACTON, MA
2 programs
Omnipod 5N/A1 trial
Omnipod 5N/A1 trial
Active Trials
NCT07317102Not Yet RecruitingEst. Nov 2027
NCT07039942RecruitingEst. Apr 2027
Jana Care
1 program
Aina HbA1c Monitoring SystemN/A1 trial
Active Trials
NCT03232437CompletedEst. Jun 2017
Kerecis
KerecisIceland - Isafjordur
1 program
Kerecis Omega3 WoundN/A1 trial
Active Trials
NCT04537520CompletedEst. Dec 2022
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Long- and intermediate- acting insulinsN/A
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Long- and intermediate- acting insulinsN/A
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
Multi-level, community-digital health promotion interventionN/A1 trial
Active Trials
NCT06607341RecruitingEst. Sep 2027
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Patient video decision aid & telephone coachingN/A1 trial
Active Trials
NCT00668590Completed201Est. Aug 2010

+4 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimEmpagliflozin
Novo Nordiskliraglutide
Novo Nordisklifestyle intervention
Novo Nordiskbiphasic insulin aspart 30
Novo Nordiskbiphasic insulin aspart 30
Novo Nordiskliraglutide
Novo Nordiskliraglutide
Novo Nordiskliraglutide
Novo Nordiskliraglutide
Novo Nordiskbiphasic insulin aspart 50
Novo Nordiskinsulin detemir
Providence TherapeuticsSwitching to NPH insulin
Novo Nordiskbiphasic insulin aspart 30
Novo Nordiskbiphasic insulin aspart 30
Novo Nordiskbiphasic insulin aspart 30

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 19,026 patients across 50 trials

NCT00663624Novo Nordiskaspart insulin

Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care

0
Phase 4Withdrawn
NCT02998970Boehringer IngelheimEmpagliflozin

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Start: Jan 2017Est. completion: Sep 201897 patients
Phase 4Unknown
NCT02730377Novo Nordiskliraglutide

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Start: Mar 2016Est. completion: Aug 20191,991 patients
Phase 4Completed
NCT02617693Novo Nordisklifestyle intervention

Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes

Start: Nov 2015Est. completion: Dec 2017552 patients
Phase 4Completed
NCT02582242Novo Nordiskbiphasic insulin aspart 30

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Start: Oct 2015Est. completion: Apr 2017437 patients
Phase 4Completed
NCT02453685Novo Nordiskbiphasic insulin aspart 30

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Start: Aug 2015Est. completion: Sep 2016335 patients
Phase 4Completed
NCT01917656Novo Nordiskliraglutide

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Start: Jan 2014Est. completion: Sep 2014343 patients
Phase 4Completed
NCT01907854Novo Nordiskliraglutide

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Start: Dec 2013Est. completion: Jun 2015407 patients
Phase 4Completed
NCT02008682Novo Nordiskliraglutide

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Start: Dec 2013Est. completion: Nov 2014368 patients
Phase 4Completed
NCT01973231Novo Nordiskliraglutide

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Start: Oct 2013Est. completion: Nov 2014404 patients
Phase 4Completed
NCT01892020Novo Nordiskbiphasic insulin aspart 50

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Start: Jun 2013Est. completion: May 2014161 patients
Phase 4Completed
NCT01868542Novo Nordiskinsulin detemir

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Start: Jun 2013Est. completion: May 201546 patients
Phase 4Completed
NCT01854723Providence TherapeuticsSwitching to NPH insulin

Comparison Study of Insulin Glargine and NPH Insulin

Start: Apr 2013Est. completion: Dec 2015
Phase 4Withdrawn
NCT01618214Novo Nordiskbiphasic insulin aspart 30

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Start: Jun 2012Est. completion: Jan 2013344 patients
Phase 4Completed
NCT01519674Novo Nordiskbiphasic insulin aspart 30

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin

Start: Jun 2012Est. completion: Oct 2013582 patients
Phase 4Completed
NCT01589653Novo Nordiskbiphasic insulin aspart 30

Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Start: May 2012Est. completion: Jul 2015155 patients
Phase 4Completed
NCT01486966Novo Nordiskinsulin detemir

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

Start: Nov 2011Est. completion: Jun 201258 patients
Phase 4Terminated
NCT01427920Novo Nordiskbiphasic insulin aspart 30

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes

Start: Sep 2011Est. completion: Jul 2012348 patients
Phase 4Completed
NCT01349114Novartisaliskiren 300 mg once daily

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Start: Jun 2011Est. completion: Jan 201221 patients
Phase 4Terminated
NCT01215435Novo Nordiskbiphasic insulin aspart 30

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Start: Mar 2011Est. completion: Sep 2012245 patients
Phase 4Completed
NCT01278160Novo Nordiskbiphasic insulin aspart 30

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Start: Jan 2011Est. completion: Sep 2011179 patients
Phase 4Completed
NCT01232491Novo NordiskInsulin detemir

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

Start: Oct 2010Est. completion: Nov 2011611 patients
Phase 4Completed
NCT01165684Novo Nordiskinsulin aspart

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Start: Oct 2010Est. completion: Apr 2012401 patients
Phase 4Completed
NCT01203774SanofiGlargine insulin

Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

Start: Sep 2010Est. completion: Aug 201343 patients
Phase 4Completed
NCT01101867Novo NordiskAspart fixed dose

Prandial Insulin Dosing in Hospitalized Patients

Start: Jun 2010Est. completion: Mar 2013126 patients
Phase 4Completed
NCT01108276ConvaTecConvatec engenex negative pressure wound therapy

Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy Device to Moist Wound Therapy

Start: May 2010Est. completion: Nov 2011
Phase 4Withdrawn
NCT01123980Novo Nordiskbiphasic insulin aspart 30

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

Start: May 2010Est. completion: Jun 2011521 patients
Phase 4Completed
NCT01068652Novo Nordiskinsulin detemir

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Start: Mar 2010Est. completion: May 2012403 patients
Phase 4Completed
NCT01022762Novo Nordiskrepaglinide

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Start: Nov 2009Est. completion: Nov 2010440 patients
Phase 4Completed
NCT00909480Novo Nordiskinsulin detemir

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes

Start: May 2009Est. completion: Jun 2010457 patients
Phase 4Completed
NCT00795600Novo Nordiskinsulin detemir

Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment

Start: Apr 2009Est. completion: Aug 201060 patients
Phase 4Completed
NCT00819741Novo Nordiskrepaglinide

Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

Start: Feb 2009Est. completion: Nov 2009433 patients
Phase 4Completed
NCT00807092Novo Nordiskbiphasic insulin aspart 30

Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes

Start: Dec 2008Est. completion: Oct 2009145 patients
Phase 4Completed
NCT00634842Novo Nordiskinsulin detemir

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Start: Feb 2008Est. completion: Oct 2008244 patients
Phase 4Completed
NCT00455858Novo Nordiskinsulin detemir

Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

Start: Nov 2007Est. completion: Oct 200887 patients
Phase 4Completed
NCT00669864Novo Nordiskbiphasic insulin aspart 30

Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Start: Nov 2007Est. completion: Apr 2009293 patients
Phase 4Completed
NCT00537303Novo Nordiskinsulin detemir

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Start: Oct 2007Est. completion: Mar 2009296 patients
Phase 4Completed
NCT00537277Novo Nordiskbiphasic insulin aspart

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs

Start: Oct 2007Est. completion: Jan 2009161 patients
Phase 4Completed
NCT00542620Novo Nordiskinsulin detemir

Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial

Start: Sep 2007Est. completion: Mar 200925 patients
Phase 4Completed
NCT00506662Novo Nordiskinsulin detemir

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes

Start: Jul 2007Est. completion: Dec 200886 patients
Phase 4Terminated
NCT00509925Novo Nordiskinsulin detemir

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Start: Jul 2007Est. completion: Jul 200823 patients
Phase 4Terminated
NCT00469092Novo Nordiskbiphasic insulin aspart

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Start: May 2007Est. completion: Apr 2008480 patients
Phase 4Completed
NCT00449839Novo NordiskInsulin Aspart

Changes of the Infusion Rate in Insulin Pump Treatment

Start: Apr 2007Est. completion: Oct 200810 patients
Phase 4Completed
NCT00521690Novo Nordiskinsulin detemir

The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD

Start: Dec 2006Est. completion: Aug 200725 patients
Phase 4Completed
NCT00313742Novo Nordiskinsulin detemir

The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins

Start: Apr 2006Est. completion: Nov 200651 patients
Phase 4Completed
NCT00282451Novo Nordiskbiphasic insulin aspart

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Start: Feb 2006Est. completion: Aug 200679 patients
Phase 4Completed
NCT00264901Novo Nordiskinsulin detemir

Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes

Start: Oct 2005Est. completion: Nov 20065,652 patients
Phase 4Completed
NCT01486862Novo Nordiskbiphasic insulin aspart 30

Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

Start: Oct 2005Est. completion: Jul 200626 patients
Phase 4Completed
NCT00309465SanofiLantus

Perioperative Insulin Glargine Dosing Study

Start: Oct 2005Est. completion: Oct 2009402 patients
Phase 4Completed
NCT00274274Novo Nordiskinsulin detemir

Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Start: Sep 2005Est. completion: Nov 2006373 patients
Phase 4Completed

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
17h ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
3d ago

Obesity Health Care B2B Manager

Eli Lilly and Company
Czech Republic, Praha 8
4d ago

Global Medical Head, Obesity

AstraZeneca
Boston - MA, US
4d ago
$283K - $425K/yr

Genomic Medicine Unit (GMU) Drug Product Development 2026 Summer-Fall Co-op

Sanofi
Waltham, MA
4d ago
$27 - $60/hr

Marketing Lead Cardiometabolic Health (w/m/d)

Eli Lilly and Company
Austria, Wien
5d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

184 late-stage (Phase 3) programs — potential near-term approvals
30 companies competing in this space

Related Indications

Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)Gout(36)